• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

    10/29/24 8:00:00 AM ET
    $AMAM
    $KURA
    $RNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMAM alert in real time by email

    – Industry veteran to serve as independent director, strengthening the board and bringing extensive leadership, executive and governance experience to Cartography as it builds out its oncology platform and pipeline -

    Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Troy E. Wilson, Ph.D., J.D., as an independent director. Dr. Wilson, a 25-year veteran of the biopharma industry, is President, CEO and co-founder of Kura Oncology (NASDAQ:KURA) and has served as chairman of its Board of Directors since it was founded in 2014.

    "We are delighted to have attracted a true industry luminary in Troy Wilson to the Cartography board," said Kevin Parker, Ph.D., CEO of Cartography Biosciences. "His extensive track record of success will prove invaluable as we move into a critical and exciting period of scientific advances, operational growth and accelerating clinical activity. Troy founded or co-founded multiple biotech companies and led those organizations through the stages of formation, clinical strategy development, rapid growth and commercialization. He has also been central to the successful exits of multiple biopharma organizations. We couldn't ask for a more qualified director, and I am personally looking forward to benefiting from his executive insights and governance acumen."

    "Cartography is doing important work to discover and develop novel therapies for patients with cancer," said Dr. Wilson. "With so many companies crowding into a handful of established targets, new therapeutic targets are urgently needed, and Cartography is doing truly pioneering work to deliver new treatment options. Cartography's approach, using its single-cell atlases to identify cell specific targets and target pairs, is an exciting one with the potential to develop effective targeted therapies with fewer risks to healthy cells and tissues. To that end, I am pleased to join the board as an independent director, and I look forward to working with Kevin and the team as they advance their pipeline of novel programs into the clinic."

    Dr. Wilson is a serial entrepreneur with a passion to build exceptional companies that create significant value for patients, employees and shareholders. Prior to Kura, he co-founded and served as President and CEO of Avidity Biosciences (NASDAQ:RNA) where he has served as chairman of its board of directors since inception. He also co-founded and served as President and CEO of Araxes Pharma LLC and Wellspring Biosciences, where his team pioneered the discovery and development of KRAS G12C selective small molecule inhibitors. Earlier in his career, Dr. Wilson co-founded and served as President and CEO of Intellikine, a private biopharmaceutical company, acquired by Takeda Pharmaceutical Company Limited in 2011, and he co-founded and served as chief business officer of Ambrx (NASDAQ:AMAM), acquired by Johnson & Johnson Innovative Medicines in 2024. He has also been a member of the Board of Directors of Puma Biotechnology, Inc., a publicly held biopharmaceutical company, since October 2013.

    Dr. Wilson holds a J.D. from New York University and graduated with a Ph.D. in bioorganic chemistry and a B.A. in biophysics from the University of California, Berkeley.

    About Cartography Biosciences

    Cartography Biosciences is building a differentiated oncology pipeline of antibody-based therapies designed to target tumors more precisely than existing therapeutics. Cartography's ATLAS and SUMMIT drug discovery platforms are powered by an industry-leading, fully integrated dataset spanning over a thousand cell types across the healthy body and large-scale profiling of individual cells from patient tumors. By leveraging petabytes of proprietary data, along with insights from machine learning and AI, Cartography is identifying and developing therapeutics against highly specific targets and target pairs to build a pipeline of molecules with the greatest patient impact. Cartography's lead program in preclinical development, CB21, is a T-cell engager being advanced for colorectal cancer (CRC). To learn more about Cartography and our mission to treat every patient with cancer, visit cartography.bio and follow us on LinkedIn and X @cartographybio.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241029358268/en/

    Get the next $AMAM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • What is the purpose of Troy E. Wilson's appointment as an independent director for Cartography?

      The appointment of Troy E. Wilson aims to strengthen Cartography's board as they advance their oncology pipeline.

    • What qualifications does Troy E. Wilson bring to Cartography Biosciences?

      Troy Wilson has over 25 years of experience in the biopharma industry, serving as the CEO and co-founder of Kura Oncology and having previously co-founded several other successful biotech companies.

    • What goals does Cartography have in relation to cancer therapy development with Dr. Wilson on board?

      Under Dr. Wilson’s guidance, Cartography aims to explore new and precise therapeutic targets for cancer treatments that minimize risks to healthy cells.

    • What is the current focus of Cartography Biosciences' lead program in development?

      Cartography's lead program, CB21, is a T-cell engager currently undergoing preclinical development specifically for colorectal cancer.

    • What notable leadership positions has Troy Wilson held prior to joining Cartography?

      Dr. Wilson previously served in various leadership roles at biotech firms, including Avidity Biosciences and Intellikine, emphasizing his strong entrepreneurial background and success in the industry.

    Recent Analyst Ratings for
    $AMAM
    $KURA
    $RNA

    CompanyDatePrice TargetRatingAnalyst
    Kura Oncology Inc.
    $KURA
    9/4/2025Neutral
    Guggenheim
    Avidity Biosciences Inc.
    $RNA
    7/10/2025$55.00Buy
    Goldman
    Avidity Biosciences Inc.
    $RNA
    6/24/2025$50.00Outperform
    Bernstein
    Avidity Biosciences Inc.
    $RNA
    6/17/2025$55.00Outperform
    Wolfe Research
    Avidity Biosciences Inc.
    $RNA
    6/11/2025$65.00Strong Buy
    Raymond James
    Avidity Biosciences Inc.
    $RNA
    3/13/2025$70.00Buy
    Citigroup
    Avidity Biosciences Inc.
    $RNA
    3/12/2025$72.00Outperform
    BMO Capital Markets
    Avidity Biosciences Inc.
    $RNA
    3/7/2025$70.00Sector Outperform
    Scotiabank
    More analyst ratings

    $AMAM
    $KURA
    $RNA
    SEC Filings

    View All

    SEC Form 144 filed by Avidity Biosciences Inc.

    144 - Avidity Biosciences, Inc. (0001599901) (Subject)

    9/5/25 4:10:14 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Avidity Biosciences Inc.

    10-Q - Avidity Biosciences, Inc. (0001599901) (Filer)

    8/7/25 4:26:17 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Kura Oncology Inc.

    10-Q - Kura Oncology, Inc. (0001422143) (Filer)

    8/7/25 4:16:58 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMAM
    $KURA
    $RNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Cormorant Asset Management, Lp bought $19,625,601 worth of Ordinary Shares (2,152,738 units at $9.12)

    4 - Ambrx Biopharma Inc. (0001836056) (Issuer)

    9/19/23 4:49:06 PM ET
    $AMAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMAM
    $KURA
    $RNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Boyce Sarah exercised 50,000 shares at a strike of $1.24 and sold $2,497,435 worth of shares (50,000 units at $49.95) (SEC Form 4)

    4 - Avidity Biosciences, Inc. (0001599901) (Issuer)

    9/5/25 6:56:01 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Mosbrooker Eric exercised 6,563 shares at a strike of $9.05 and sold $308,936 worth of shares (6,563 units at $47.07) (SEC Form 4)

    4 - Avidity Biosciences, Inc. (0001599901) (Issuer)

    9/5/25 6:32:51 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Program Officer Gallagher Kathleen P. sold $8,915 worth of shares (188 units at $47.42), decreasing direct ownership by 0.37% to 50,204 units (SEC Form 4)

    4 - Avidity Biosciences, Inc. (0001599901) (Issuer)

    9/2/25 8:30:31 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMAM
    $KURA
    $RNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $AMAM
    $KURA
    $RNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on September 2, 2025, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of nonstatutory stock options to purchase 82,950 shares of common stock to seven (7) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq L

    9/5/25 7:30:00 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program

    September 16 event to highlight preclinical data on the combination of FTI agents with multiple classes of targeted therapies October 18 event to review clinical data from the ESMO Congress 2025, including first clinical data from KO-2806 SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for cancer, today announced it will host two virtual investor and analyst events to spotlight its innovative farnesyl transferase inhibitor (FTI) program. These events will underscore Kura's leadership in targeting cancer signaling pathways to address unmet needs in solid tu

    9/3/25 8:02:00 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kura Oncology to Participate in Three Upcoming Investor Conferences

    SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that management is scheduled to participate in three investor conferences in September. Cantor Global Health ConferenceThursday, September 4, 20258:35 a.m. ET / 5:35 a.m. PT H.C. Wainwright 27th Annual Global Investment ConferenceMonday, September 8, 20251:00 p.m. ET / 10:00 a.m. PT Morgan Stanley 23rd Annual Global Healthcare ConferenceWednesday, September 10, 20251:50 p.m. ET / 10:50 a.m. PT Live audio webcasts will be available in the Investors section of Kura'

    8/28/25 7:30:00 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Kura Oncology

    Guggenheim initiated coverage of Kura Oncology with a rating of Neutral

    9/4/25 9:01:23 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman resumed coverage on Avidity Biosciences with a new price target

    Goldman resumed coverage of Avidity Biosciences with a rating of Buy and set a new price target of $55.00

    7/10/25 8:52:40 AM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bernstein initiated coverage on Avidity Biosciences with a new price target

    Bernstein initiated coverage of Avidity Biosciences with a rating of Outperform and set a new price target of $50.00

    6/24/25 7:59:27 AM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMAM
    $KURA
    $RNA
    Leadership Updates

    Live Leadership Updates

    View All

    OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee

    PRESS RELEASE OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics (‘OMass' or ‘the Company'), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee. Carol has more than 25 years of experience in investment banking, equity capital markets, corporate finance and business development in the healthcare sector. She currently serves on the Board of Directors for Insmed Incorporated (NAS

    8/6/25 7:00:00 AM ET
    $IMNM
    $INSM
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

    – Industry veteran to serve as independent director, strengthening the board and bringing extensive leadership, executive and governance experience to Cartography as it builds out its oncology platform and pipeline - Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Troy E. Wilson, Ph.D., J.D., as an independent director. Dr. Wilson, a 25-year veteran of the biopharma industry, is President, CEO and co-founder of Kura Oncology (NASDAQ:KURA) and has served as chairman of its Board of Directors since it was founded in 2014. "We are delighted to have attracted a true industry

    10/29/24 8:00:00 AM ET
    $AMAM
    $KURA
    $RNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors

    SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Michael Vasconcelles, M.D., to its Board of Directors. Dr. Vasconcelles is an accomplished biopharmaceutical executive with more than 25 years of oncology drug development experience and industry leadership. "On behalf of our Board and leadership team, we are delighted to have Mike join our Board of Directors," said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. "His extensive experience in R&D and regulatory aff

    9/17/24 7:30:00 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMAM
    $KURA
    $RNA
    Financials

    Live finance-specific insights

    View All

    Kura Oncology Reports Second Quarter 2025 Financial Results

    – FDA Priority Review of New Drug Application (NDA) for ziftomenib in adults with R/R NPM1-m AML with Prescription Drug User Fee Act (PDUFA) target action date set for November 30, 2025 – – Fully engaged in commercial readiness activities in alignment with regulatory review timeline – – KOMET-017-IC (intensive chemotherapy) and NIC (non-intensive chemotherapy) phase 3 studies in newly diagnosed AML on track to start in 2H 2025 – – Three clinical abstracts from Kura's farnesyl transferase inhibitors (FTI) development program accepted for presentation at the 2025 ESMO Congress – – $630.7 million in pro forma cash, together with anticipated collaboration agreement payments, expected to supp

    8/7/25 4:05:00 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kura Oncology to Report Second Quarter 2025 Financial Results

    SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report second quarter 2025 financial results after the close of U.S. financial markets on Thursday, August 7, 2025. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the financial results and provide a corporate update. The live call may be accessed by dialing (800) 579-2543 for domestic callers and (785) 424-1789 for international callers and entering the conference ID: KURAQ2. A live webcast and archived rep

    7/31/25 7:30:00 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kura Oncology Reports First Quarter 2025 Financial Results

    – NDA submitted in 1Q 2025 for ziftomenib for the treatment of adult patients with relapsed or refractory AML with an NPM1 mutation – – Data from Phase 1b/2 registration-directed trial of ziftomenib selected for oral presentation at ASCO Annual Meeting – – $45.0 million milestone payment earned for NDA submission under collaboration agreement with Kyowa Kirin – – First patients dosed in Phase 1 trial of ziftomenib plus imatinib in GIST – – $703.2 million in pro forma cash, together with anticipated collaboration agreement payments, expected to support ziftomenib commercialization through the frontline AML combination setting – – Management to host webcast and conference call today at 4:

    5/1/25 4:05:00 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMAM
    $KURA
    $RNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Kura Oncology Inc.

    SC 13G - Kura Oncology, Inc. (0001422143) (Subject)

    12/5/24 6:55:37 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Avidity Biosciences Inc.

    SC 13G/A - Avidity Biosciences, Inc. (0001599901) (Subject)

    11/14/24 5:46:11 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kura Oncology Inc.

    SC 13G/A - Kura Oncology, Inc. (0001422143) (Subject)

    11/14/24 4:31:29 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care